3rd Retinal Imaging Biomarkers and Endpoints Summit

Accelerate Your Ophthalmic Development with Deep Learning Systems and Sophisticated AI Imaging Technologies...

With state-of-the-art AI-assisted technology making retinal imaging 100 times faster, the rapid advancement of technology in ophthalmology, coupled with the strong unmet need for more drugs for retinal diseases, highlights the urgency of continued focus and progress in this space. This need is emphasized by Merck's recent $3 billion acquisition of EyeBio. In light of this, as we move into 2025 and beyond, there is a real need to re-unite the retinal imaging biomarkers and endpoints community to align efforts and propel the field to new heights.

Time: 8:00 AM - 5:00 PM